Login
Navigate Fool.com
Will CADX beat
the market?
Community Rating: 2 Stars: Unattractive

0.00 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.00
Previous Close $0.00
Daily Range $0.00 - $0.00
52-Week Range $0.00 - $0.00
Market Cap $0.00
P/E Ratio -49.93
Dividend (Yield) $0.00 (0.0%)
Volume 0
Average Daily Volume 0
Current FY EPS $0.13

How do you think CADX
will perform against the market?

Top CADX Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

NetscribeBiotech (< 20)
Submitted March 22, 2007

Cadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on in licensing, developing and ultimately commercializing its product candidates principally for use in the hospital set … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Mallinckrodt plc Takes a Big Swing for Growth

In buying Questcor, Mallinckrodt is acquiring exceptional potential for earnings, controversy, and disappointment

This Week in Biotech: Three Strikes and You're Out!

The FDA and its advisory panel give a thumbs down to three experimental drugs, while buyout mania strikes the biotech sector.

Everyone Wins in This Big Pharma Buyout

Here's one pharmaceutical buyout that the market loved on all sides.

Why Cadence Pharmaceuticals, Relypsa, and Hansen Medical Are Today's 3 Best Stocks

The S&P 500 soars again thanks to the "Yellen effect," while Cadence Pharmaceuticals, Relypsa, and Hansen Medical all advance by double-digits.

Mid-Afternoon Market Update: Markets Continue to Rally as InfoBlox Takes a Big Haircut

Sector Update: Healthcare

Why Mallinckrodt PLC Shares Popped

Is this meaningful or just another movement?

Mallinckrodt May Have to Pay More for Cadence

Today’s Top Biotech Stories: Mallinckrodt, Regeneron, Arena, and Omeros

Mallinckrodt, Regeneron, Arena, and Omeros could all loom large in health care headlines this morning. Here’s why.

This Week in Biotech

An FDA approval, a company more than doubling in value following an FDA advisory panel decision, and another which lost 60% following comments from the FDA are among this week's top biotech stories.

See More CADX News...

Sector

Healthcare

Industry

Drugs

Cadence Pharmaceuticals, Inc. (CADX) Description

A biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. Website: http://www.cadencepharm.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks